Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...

NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

Tiziana Life Sciences ( ($TLSA) ) has shared an update. On February 25, 2025, Tiziana Life Sciences announced the nearing completion of a ...

In this article, we are going to take a look at where Tiziana Life Sciences Ltd (NASDAQ:TLSA) stands against the other biotech stocks. No matter the market environment, you’ll always find ...

Tiziana Life Sciences, Ltd. has entered into a product development services agreement with Renaissance Lakewood LLC to enhance and scale up the formulation of its lead candidate, intranasal ...

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana” or the "Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...